KAI Pharmaceuticals
10
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
1 terminated/withdrawn out of 10 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
Role: lead
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia
Role: lead
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Role: lead
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
Role: lead
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
Role: lead
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Role: lead
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
Role: lead
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Role: lead
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Role: lead
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
Role: lead
All 10 trials loaded